10 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European Prevention of Alzheimer’s Dementia Consortium (EPAD)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet
40
Participants partenaires
TERMINÉ
Explore novel connections between oncogenic pathways in lung cancer (NOTCHLUNG)
Date du début: 1 mars 2014, Date de fin: 28 févr. 2018,
"Lung cancer causes about a million deaths per year and the estimation is that 250 million people will die during the 21st century for this reason. A major challenge in treating this and other cancers is the intrinsic resistance to conventional therapies demonstrated by the cancerous cells that are responsible for the sustained growth, survival, and invasion of the tumour. Identifying new pathways ...
Voir le projet
1
Participant partenaire
TERMINÉ
Notch and epithelial proliferation (PRONO)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
"During development the different organs and tissues of an organism have to grow harmoniously to reach their specific shapes and sizes. In the adult, organs have usually reached an equilibrium, where loss of cells must be compensated by tightly regulated proliferation. During cancer, groups of cells evade these controls and start to proliferate abnormally.The Notch intercellular signalling pathway ...
Voir le projet
1
Participant partenaire
TERMINÉ
The Role of Beta-Adrenergic Signaling in Cardiac Progenitor Cell Activation after Myocardial Infarction (Heart Betas)
Date du début: 14 avr. 2015, Date de fin: 13 avr. 2017,
Cardiovascular diseases are a leading cause of mortality in the industrialized world with myocardial infarction (MI) being one of the common pathological events. Cardiac progenitor cells (CPC) are a progenitor cell population within the myocardium and are activated after MI to proliferate, migrate to the infarct site, and participate in cardiac regeneration. CPC are a current therapeutic target to ...
Voir le projet
1
Participant partenaire
TERMINÉ
"From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" (BRAINVECTORS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
"BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression.Although AAV, CAV and LVV are considered acc ...
Voir le projet
12
Participants partenaires
TERMINÉ
Training Network on Zebrafish Infection Models for Pharmaceutical Screens (FishForPharma)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
Infectious diseases caused by pathogenic micro-organisms are major causes of death, disability, and social and economic disruption for millions of people. During evolution these pathogens have developed intricate strategies to manipulate host defence mechanisms and outwit the immune system. To reduce the burden of infectious diseases it is important to increase understanding of these host-pathogen ...
Voir le projet
10
Participants partenaires
TERMINÉ
Ovarian Cancer Therapy – Innovative Models Prolong Survival (OCTIPS)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
"About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimately acquire platinum resistance which soon leads to death. Relapsed high grade serous ovarian cancer (HGSOC) is the single main cause of EOC-related morbidity and mortality (despite the fact that HGSOC is highly chemosensitive). We hypothesize that the primary ...
Voir le projet
11
Participants partenaires
TERMINÉ
Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance (OVER-MYR)
Date du début: 1 janv. 2012, Date de fin: 30 juin 2015,
Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and c ...
Voir le projet
11
Participants partenaires
TERMINÉ
The role of heterochromatin enzymes on the biology of their targets (PICHV2.0)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,
The control of DNA based processes in biology is crucial for an organism s life, development, reproduction and evolution. In fact, deregulation of gene expression, of the replication program, of DNA repair or recombination has often disastrous consequences. The eukaryotic genome is structurally and functionally organized into chromatin by a highly complex mixture of proteins that control access to ...
Voir le projet
1
Participant partenaire
TERMINÉ
Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders (BIO-NMD)
Date du début: 1 déc. 2009, Date de fin: 30 nov. 2012,
"The rapidly expanding knowledge of NMDs genetic diagnosis, pathogenesis and therapeutic possibilities has provided new targets for disease characterisation, early diagnosis, drug discovery and development as well as has raised many questions about how to translate this knowledge into clinical practice as (initial) clinical trials typically run for such a short time that clinical improvement can h ...
Voir le projet